狼疮的治疗方法综述。

Q2 Medicine

Senior Care Pharmacist Pub Date : 2025-03-01 DOI:10.4140/TCP.n.2025.135

Creaque C Tyler, Aireona C Armagon, Ildebrando E Garcia, Angie Eaton

{"title":"狼疮的治疗方法综述。","authors":"Creaque C Tyler, Aireona C Armagon, Ildebrando E Garcia, Angie Eaton","doi":"10.4140/TCP.n.2025.135","DOIUrl":null,"url":null,"abstract":"Lupus treatment recently saw the approval of new drugs after a 12-year gap since the last approval of belimumab (Benlysta) in 2011. This article reviews these newly FDA-approved agents, which have demonstrated efficacy and safety in the management of systemic lupus erythematosus and lupus nephritis, a severe complication of the disease.","PeriodicalId":41635,"journal":{"name":"Senior Care Pharmacist","volume":"40 3","pages":"135-144"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Review of Therapeutics for the Treatment of Lupus.\",\"authors\":\"Creaque C Tyler, Aireona C Armagon, Ildebrando E Garcia, Angie Eaton\",\"doi\":\"10.4140/TCP.n.2025.135\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Lupus treatment recently saw the approval of new drugs after a 12-year gap since the last approval of belimumab (Benlysta) in 2011. This article reviews these newly FDA-approved agents, which have demonstrated efficacy and safety in the management of systemic lupus erythematosus and lupus nephritis, a severe complication of the disease.\",\"PeriodicalId\":41635,\"journal\":{\"name\":\"Senior Care Pharmacist\",\"volume\":\"40 3\",\"pages\":\"135-144\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Senior Care Pharmacist\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4140/TCP.n.2025.135\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Senior Care Pharmacist","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4140/TCP.n.2025.135","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

自2011年贝利木单抗（Benlysta）获得批准以来，狼疮治疗领域时隔12年又有新药获得批准。本文回顾了这些新近获得美国食品和药物管理局批准的药物，它们在治疗系统性红斑狼疮和狼疮肾炎（该病的一种严重并发症）方面显示出了疗效和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A Review of Therapeutics for the Treatment of Lupus.

Lupus treatment recently saw the approval of new drugs after a 12-year gap since the last approval of belimumab (Benlysta) in 2011. This article reviews these newly FDA-approved agents, which have demonstrated efficacy and safety in the management of systemic lupus erythematosus and lupus nephritis, a severe complication of the disease.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Senior Care Pharmacist PHARMACOLOGY & PHARMACY-

CiteScore

1.30

自引率

0.00%

发文量

160